The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Staff who provide data to the vaccine panel have been pushed aside, according to health officials, raising doubts about the ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Health and Human Services Secretary Robert F. Kennedy, Jr., has announced new members of the Centers for Disease Control and ...

Some of the panel's new members are anti-vaccine or clearly focus their attention on adverse reactions to vaccines.

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

Global Oral Antiviral Market is valued approximately USD 36.7 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 2.10% over the forecast period 2024-2032. Read the ...